Global Disparities in Current Clinical Trials in Nasopharyngeal Carcinoma
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Nasopharyngeal carcinoma (NPC) clinical trials are not geographically representative, with low-income countries underrepresented. Radiation therapy (RT) is also underinvestigated in these crucial trials.
Area Of Science
- Oncology
- Clinical Trials Research
- Global Health Disparities
Background
- Nasopharyngeal carcinoma (NPC) disproportionately affects East/Southeast Asia and North Africa.
- Clinical trials are essential for evidence-based care but their geographic representation is unclear.
- Radiation therapy (RT) is a cornerstone of NPC treatment.
Purpose Of The Study
- To analyze the geographic distribution of NPC clinical trials.
- To assess the representation of endemic countries in NPC trials.
- To evaluate the investigation of radiation therapy (RT) in NPC clinical trials.
Main Methods
- Phase 2 and 3 NPC clinical trials from 2013-2023 were identified via ClinicalTrials.gov.
- Endemic countries were defined using GLOBOCAN 2022 incidence rates.
- Trial interventions and country of origin were systematically analyzed.
Main Results
- 266 trials were analyzed; 50% focused on immunotherapy/targeted therapy, 30% on chemotherapy, and 9% on RT.
- China dominated trial origins (80%), followed by the US (4.5%).
- Only 17% of NPC-endemic countries were represented in international trials, with lower-income nations severely underrepresented.
Conclusions
- Significant geographic and income-based disparities exist in NPC clinical trials.
- Lower-income endemic countries are critically underrepresented in research.
- Increased global collaboration is needed to include diverse populations and researchers.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Biases can arise at various stages of research, from study design and data collection to analysis and interpretation. Recognizing and addressing these biases is essential to ensure the validity and reliability of epidemiological findings.Broadly speaking, biases in epidemiology fall into three main categories: selection bias, information bias, and confounding. A more detailed description of possible biases is:
Selection Bias: This occurs when the study population is not...
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...